Diabetes Drug vs Weight Loss Drug
Mounjaro (tirzepatide) and Wegovy (semaglutide) are both effective for weight loss, but have different FDA indications that affect insurance coverage and prescribing.
We've reviewed patient-reported experiences to help you understand the practical differences between these medications.
Prices re-read November 18, 2026
Mounjaro costs $1,399 every 4 weeks (about $1,515.58 a month) at Physicians Weight Loss Centers, the cheapest verified Mounjaro price among the providers our tracker re-read in the last 36 hours. Wegovy costs $349 every 4 weeks (about $378.08 a month) at NovoCare / Wegovy Direct, the cheapest verified Wegovy price among the providers our tracker re-read in the last 36 hours. Compounded tirzepatide injections start at $118 a month, month to month, at FlatRx; the cheapest month-to-month prices are $118 at FlatRx, $129 at Eden and $129 at Embody among the 43 providers whose tirzepatide prices our tracker re-read in the last 36 hours. Compounded semaglutide injections start at $79 a month, month to month, at Embody; the cheapest month-to-month prices are $79 at Embody, $99 at Eden and $99 at FlatRx among the 45 providers whose semaglutide prices our tracker re-read in the last 36 hours. Compounded medication is not FDA-approved. Prices read on each provider's own site on November 18, 2026.
$1,399 every 4 weeks (about $1,515.58 a month)
at Physicians Weight Loss CentersRead on November 18, 2026 at 12:44 UTC on hub.wellsync.com/en-US/pwlc/conditions/weight-loss/weight-loss/drugs
Cheapest verified Mounjaro price, as the provider words it.
$349 every 4 weeks (about $378.08 a month)
at NovoCare / Wegovy DirectRead on November 18, 2026 at 12:41 UTC on novocare.com/pharmacy.html
Cheapest verified Wegovy price, as the provider words it.
Cheapest month-to-month prices, one per provider, ordered by price alone (43 providers re-read).
Cheapest month-to-month prices, one per provider, ordered by price alone (45 providers re-read).
Read by our tracker on each provider’s own site. AllGLP1 may earn a commission if you sign up through a link above; it never changes the prices shown or their order.
Side-by-side comparison of reported experiences
| Feature | Mounjaro | Wegovy | Source Notes |
|---|---|---|---|
| Active Ingredient | Tirzepatide | Semaglutide | Different molecules |
| Mechanism | Dual GIP/GLP-1 | GLP-1 only | Mounjaro dual action |
| Typical Weight Loss | 20.2% | 13.7% | SURMOUNT-5 head-to-head trial |
| Primary Indication | Type 2 Diabetes | Weight Loss | FDA-approved uses differ |
| Max Dose | 15mg weekly | 2.4mg weekly | Per prescribing information |
| Brand Cost (Self-Pay) | $399-549/mo (vials) | $349-499/mo (NovoCare) | 2026 self-pay pricing programs |
| Insurance | Better (T2D) | Limited | Diabetes indication easier to cover |
| Cardiovascular Data | 42% lower MACE risk* | 20% MACE reduction | *Nature Medicine 2025 (T2D) |
Different molecules
Mounjaro dual action
SURMOUNT-5 head-to-head trial
FDA-approved uses differ
Per prescribing information
2026 self-pay pricing programs
Diabetes indication easier to cover
*Nature Medicine 2025 (T2D)
Figures in this table were typed when the page was written and may be out of date; today's verified prices are in the cost box above.
Data from the SURMOUNT-5 & Nature Medicine (2025) (NEJM / Nature Medicine)
While Mounjaro is indicated for Type 2 diabetes and Wegovy for weight management, they contain the two most potent weight-loss molecules ever studied. Recent head-to-head and real-world data provide a clear picture of their relative effectiveness.
| Comparison Metric | Mounjaro | Wegovy |
|---|---|---|
| Max Weight Loss (%) | 20.2% | 13.7% |
| Cardiovascular Risk | 42% Lower MACE risk* | 20% MACE reduction |
| Lost >20% Body Weight | 52.5% | 28.1% |
| HbA1c Reduction | Up to 2.3% | Up to 1.8%* |
| Mechanism | Dual GIP/GLP-1 | Single GLP-1 |
"Mounjaro (tirzepatide) offers superior weight loss and potentially greater cardiovascular protection in diabetic populations (Nature Medicine 2025). However, Wegovy remains the gold standard for weight loss in patients without diabetes due to its specific FDA indication and long-term safety profile in that population."
Results were statistically significant (p < 0.001) across all primary endpoints.
Latest verification performed January 2026.
Answer these 3 questions to see your best match:
Take our 90-second quiz for personalized provider recommendations ranked by your insurance + budget.
Start QuizPatient-reported side effect patterns
Drawing from patient-reported strategies
Real questions from Mounjaro users
Common questions from Mounjaro users
Not sure which is right for you?
🎯Take Our 2-Minute Quiz